SanofiSNY stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent, a ...

Sanofi shares plunged after its experimental drug for the skin condition atopic dermatitis disappointed investors with a less ...

Amlitelimab study met its goals but results were not meaningfully better than Dupixent ...

Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...

Sanofi stated that these positive results strengthen amlitelimab's potential as a treatment for atopic dermatitis. The company is currently conducting additional late-stage trials of the drug, which ...

Amlitelimab has been billed by Sanofi as a successor to its Regeneron-partnered, $14.5 billion blockbuster Dupixent ...

French drugmaker Sanofi SA (NASDAQ:SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its ...

Amlitelimab showed efficacy in skin clearance compared to a placebo, but the results underwhelmed investors.

An effort by President Trump’s administration to curb advertising for pharmaceutical drugs on television is posing a ...

Eczema can be very distressing for children – and now it seems that its roots may at least partly lie in their mothers ...

European shares closed higher on Thursday as heightened expectations for a U.S. Federal Reserve interest rate cut lifted ...

Enveda has closed its second $150 million financing round of the year. The series D round, which moves Enveda’s total funding ...